Skip to Content
Søk Menu

SABCS | San Antonio Breast Cancer Symposium

SABCS 2025

SABCS 2025: Favorable Benefit–Risk Profile of Sacituzumab Govitecan in Previously Untreated Metastatic TNBC PD-L1–ineligible Metastatic Triple-Negative Breast Cancer

/ Jan Andreasen
BrystkreftSABCS25
Kirsten Marie Woolpert

SABCS 2025: Patterns of Opioid Use Among Breast Cancer Survivors

/ Kirsten Marie Woolpert
BrystkreftNBCNSABCS25 Play the Video

SABCS 2023

Hatem Azim

Using Fertility Options May be Safe for Patients with HR-positive Breast Cancer

/ Hatem Azim
BrystkreftSABCS23 Play the Video

Onkologi / Hematologi (Nr. 10 • 2023)

Få tilgang
Terry Mamounas

The Effectiveness of Regional Nodal Radiation in Patients with Breastcancer

/ Eleftherios (Terry) P. Mamounas
BrystkreftSABCS23 Play the Video

SABCS 2023: HR-Positive Breast Cancer Patients May Safely Use Fertility Options

/ BestPractice Nordic
BrystkreftSABCS23

SABCS 2023: Younger Postmenopausal Women May Safely Skip Adjuvant Radiotherapy

/ BestPractice Nordic
BrystkreftSABCS23

SABCS 2023: Neoadjuvant Chemotherapy: May Reduce Regional Nodal Irradiation in Breast Cancer Patients

/ BestPractice Nordic
BrystkreftSABCS23

SABCS 2023: Blood Hormone Levels: A Key to Effective Breast Cancer Prevention in Post-Menopausal Women

/ BestPractice Nordic
BrystkreftSABCS23

BestPractice Nordic is covering SABCS 2023

/ BestPractice Nordic
BrystkreftSABCS23

SABCS 2022

Elsebeth Lynge

Does breast density affect the risk of breast cancer?

/ Elsebeth Lynge
BrystkreftSABCS22 Play the Video

Lav dosis acetylsalicylsyre - Potentiel effekt mod tilbagevendende brystkræft

/ BestPractice Nordic
BrystkreftSABCS22

Type 2 diabetes and breast cancer surgery – increased risk of postoperative complications

/ BestPractice Nordic
BehandlingBrystkreftSABCS22Type 2-diabetes

Neoadjuvant Enhertu and HER2-low breast cancer - Overall response rate of 75%

/ BestPractice Nordic
BehandlingBrystkreftSABCS22

Trodelvy (sacituzumab govitecan) – A new effective treatment option for breast cancer

/ BestPractice Nordic
BehandlingBrystkreftSABCS22

Interruption of endocrine therapy for pregnancy – New promising data presented at SABCS22

/ BestPractice Nordic
BrystkreftGraviditetSABCS22

SABCS 2022 – From basic science breakthroughs to practice-changing new therapies

/ BestPractice Nordic
BrystkreftSABCS22

SABCS2019

SABCS 2019: Et av de mest lovende medikamentene mot brystkreft

/ Henrik Lindman
BrystkreftSABCS19 Play the Video
Back to top